HIV, antiretroviral therapies, and the brain

Current HIV/AIDS Reports

Volumn 7, Issue 2, 2010, Pages 85-91

  Liner II, Kevin J ^a   Ro, Michelle J ^a   Robertson, Kevin R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; CNS; HIV 1; Impairment; Neurocognition

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; ETRAVIRINE; HISTONE DEACETYLASE INHIBITOR; INDINAVIR; LAMIVUDINE; MARAVIROC; MRKI; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; NANOPARTICLE; PEPTIDE T; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SOLID LIPID NANOPARTICLE; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; VICRIVIROC; ZALCITABINE; ZIDOVUDINE;

AFRICA; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ASIA; BLOOD BRAIN BARRIER; BRAIN FUNCTION; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; COGNITION; COMBINATION CHEMOTHERAPY; DAILY LIFE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PENETRATION; DRUG TRANSPORT; FUNCTIONAL STATUS; HALLUCINATION; HANGOVER; HEPATITIS B; HEPATITIS C; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; IMMUNOREGULATION; MIXED INFECTION; MULTIDRUG RESISTANCE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRACTICE GUIDELINE; REVIEW; VIRUS ACTIVATION; VIRUS REPLICATION;

AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; BRAIN; COGNITION DISORDERS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; SPINAL CORD;

EID: 77954624248     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-010-0042-8     Document Type: Review

References (56)

1. Antinori A, Arendt G, Becker JT, et al.: Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007, 69:1789-1799.
2. Robertson KR, Smurzynski M, Parsons TD, et al.: The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007, 21:1915-1921.
3. •• Ellis R: Effects of CNS antiretroviral distribution on neurocognitive impairment in the AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) Study. In 134th Annual Meeting of the American Neurolological Association. Baltimore, MD; October 11-14, 2009. The ACTG ALLRT study yields evidence that higher-ranking CPE regimens correlate with neurocognitive improvement.
4. Sterne JA, May M, Costagliola D, et al.: Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009, 373:1352-1363.
5. Tozzi V, Balestra P, Salvatori MF, et al.: Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr 2009, 52:56-63.
6. Marra CM, Zhao Y, Clifford DB, et al.: Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009, 23:1359-1366.
7. • Robertson K, Zhaohui, S, Margolis, DM, et al.: Neurocognitive effects of treatment interruption in stable HIV + patients in an observational cohort: ACTG 5170. Neurology 2010, In press. The ACTG 5170 study found that patients discontinuing HAART experienced NP improvement, raising the possibility that ART may have neurotoxic effects.
8. •• Letendre S: Revised CNS penetration-effectiveness ranks. In 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; 2010. The updated CPE rankings divide ART drugs into four categories of penetration: high, high-intermediate, low-intermediate, and low.
9. Patel K, Ming X, Williams PL, et al.: Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents. AIDS 2009, 23:1893-1901.
10. Letendre S, Marquie-Beck J, Capparelli E, et al.: Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008, 65:65-70.
11. Cysique LA, Vaida F, Letendre S, et al.: Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 2009, 73:342-348.
12. Dickinson L, Khoo S, Back D: Pharmacokinetics and drug-drug interactions of antiretrovirals: an update. Antiviral Res 2009, 85:176-189.
13. Yilmaz A, Gisslen M, Spudich S, et al.: Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One 2009, 4:e6877.
14. Yilmaz A, Izadkhashti A, Price RW, et al.: Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals. AIDS Res Hum Retroviruses 2009, 25:457-461.
15. Yilmaz A, Watson V, Else L, Gisslen M: Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients. AIDS 2009, 23:2537-2540.
16. Walker DK, Bowers SJ, Mitchell RJ, et al.: Preclinical assessment of the distribution of maraviroc to potential human immunodeficiency virus (HIV) sanctuary sites in the central nervous system (CNS) and gut-associated lymphoid tissue (GALT). Xenobiotica 2008, 38:1330-1339.
17. Hanson LR, Frey WH 2nd: Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS. J Neuroimmune Pharmacol 2007, 2:81-86.
18. Polianova MT, Ruscetti FW, Pert CB, et al.: Antiviral and immunological benefits in HIV patients receiving intranasal peptide T (DAPTA). Peptides 2003, 24:1093-1098.
19. Nowacek A, Gendelman HE: NanoART, neuroAIDS and CNS drug delivery. Nanomed 2009, 4:557-574.
20. Chattopadhyay N, Zastre J, Wong HL, et al.: Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line. Pharm Res 2008, 25:2262-2271.
21. Kuo YC, Chen HH: Entrapment and release of saquinavir using novel cationic solid lipid nanoparticles. Int J Pharm 2009, 365:206-213.
22. Bowman MC, Ballard TE, Ackerson CJ, et al.: Inhibition of HIV fusion with multivalent gold nanoparticles. J Am Chem Soc 2008, 130:6896-6897.
23. Dou H, Grotepas CB, McMillan JM, et al.: Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J Immunol 2009, 183:661-669.
24. Alexaki A, Liu Y, Wigdahl B: Cellular reservoirs of HIV-1 and their role in viral persistence. Curr HIV Res 2008, 6:388-400.
25. Han Y, Wind-Rotolo M, Yang HC, et al.: Experimental approaches to the study of HIV-1 latency. Nat Rev Microbiol 2007, 5:95-106.
26. Sahu GK, Paar D, Frost SD, et al.: Low-level plasma HIVs in patients on prolonged suppressive highly active antiretroviral therapy are produced mostly by cells other than CD4 T-cells. J Med Virol 2009, 81:9-15.
27. Schnell G, Spudich S, Harrington P, et al.: Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia. PLoS Pathog 2009, 5:e1000395.
28. Richman DD, Margolis DM, Delaney M, et al.: The challenge of finding a cure for HIV infection. Science 2009, 323:1304-1307.
29. Archin NM, Keedy KS, Espeseth A, et al.: Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS 2009, 23:1799-1806.
30. Cysique LA, Brew BJ: Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review. Neuropsychol Rev 2009, 19:169-185.
31. Schweinsburg BC, Taylor MJ, Alhassoon OM, et al.: Brain mitochondrial injury in human immunodeficiency virusseropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. J Neurovirol 2005, 11:356-364.
32. • Liner J, Robertson K, Meeker R: Antiretroviral neurotoxicity. Poster presented at 39th Annual Neuroscience Meeting. Chicago, IL; 2009. This study demonstrates the potential neurotoxic mechanisms of ART on neuronal cultures.
33. Ellis R, Langford D, Masliah E: HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci 2007, 8:33-44.
34. Hammer SM, Eron JJ Jr, Reiss P, et al.: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008, 300:555-570.
35. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed March 2, 2010.
36. Kitahata MM, Gange SJ, Abraham AG, et al: Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009, 360:1815-1826.
37. Ances BM, Sisti D, Vaida F, et al.: Resting cerebral blood flow: a potential biomarker of the effects of HIV in the brain. Neurology 2009, 73:702-708.
38. Marcondes MC, Flynn C, Huitron-Rezendiz S, et al.: Early antiretroviral treatment prevents the development of central nervous system abnormalities in simian immunodeficiency virus-infected rhesus monkeys. AIDS 2009, 23:1187-1195.
39. Villar Del Saz S, Sued O, Falco V, et al.: Acute meningoencephalitis due to human immunodeficiency virus type 1 infection in 13 patients: clinical description and follow-up. J Neurovirol 2008, 1-6.
40. Harrington PR, Schnell G, Letendre SL, et al. Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course. Aids 2009,23:907-915.
41. Gorman AA, Foley JM, Ettenhofer ML, et al.: Functional consequences of HIV-associated neuropsychological impairment. Neuropsychol Rev 2009, 19:186-203.
42. Owe-Larsson B, Sall L, Salamon E, Allgulander C: HIV infection and psychiatric illness. Afr J Psychiatry (Johannesbg) 2009, 12:115-128.
43. Gutierrez-Valencia A, Viciana P, Palacios R, et al.: Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial. Ann Intern Med 2009, 151:149-156.
44. Morgan EE, Woods SP, Weber E, et al.: HIV-associated episodic memory impairment: evidence of a possible differential deficit in source memory for complex visual stimuli. J Neuropsychiatry Clin Neurosci 2009, 21:189-198.
45. Woods SP, Iudicello JE, Moran LM, et al.: HIV-associated prospective memory impairment increases risk of dependence in everyday functioning. Neuropsychology 2008, 22:110-117.
46. Hubben GA, Bishai D, Pechlivanoglou P, et al.: The societal burden of HIV/AIDS in Northern Italy: an analysis of costs and quality of life. AIDS Care 2008, 20:449-455.
47. Zachariah R, Ford N, Philips M, et al.: Task shifting in HIV/AIDS: opportunities, challenges and proposed actions for sub-Saharan Africa. Trans R Soc Trop Med Hyg 2009, 103:549-558.
48. Robertson K, Liner J, Heaton R: Neuropsychological assessment of HIV-infected populations in international settings. Neuropsychol Rev 2009,19:232-249.
49. • Robertson K, Jiang H, Tripathy S, et al.: Improved neuropsychological function during HAART in diverse resource-limited settings: AIDS Clinical Trials Group Study A5199, the International Neurological Study. In 16th Conference on Retroviruses and Opportunistic Infections. Montreal, CA; 2009. The ACTG 5199 study spanning seven developing countries reveals that ART is associated with NP improvement internationally, though the magnitude of improvement varies by country.
50. Heaton RK, Cysique LA, Jin H, et al.: Neurobehavioral effects of human immunodeficiency virus infection among former plasma donors in rural China. J Neurovirol 2008, 1-14.
51. Cysique LA, Jin H, Franklin DR Jr, et al.: Neurobehavioral effects of HIV-1 infection in China and the United States: a pilot study. J Int Neuropsychol Soc 2007, 13:781-790.
52. Valcour VG, Shiramizu BT, Sithinamsuwan P, et al.: HIV DNA and cognition in a Thai longitudinal HAART initiation cohort: the SEARCH 001 Cohort Study. Neurology 2009, 72:992-998.
53. Sacktor N, Nakasujja N, Skolasky RL, et al.: Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda. Neurology 2009, 72:165-170.
54. NeuroAIDS in Africa. http://synapse.neurology.unc.edu/capetown/ program.htm. Accessed March 2, 2010.
55. Sacktor N, Nakasujja N, Skolasky RL, et al.: HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda. Clin Infect Dis 2009, 49:780-786.
56. Gupta JD, Satishchandra P, GopukumarK, et al.: Neuropsychological deficits in human immunodeficiency virus type 1 clade C-seropositive adults from South India. J Neurovirol 2007, 13:195-202.